Drug Profile
Iboctadekin
Alternative Names: 485232; IL-18 - GSK; Interleukin-18 - GSK; Recombinant human interleukin-18 - GSK; rhIL-18; SB-485232Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator Hayashibara Biochemical Laboratories; Hyogo College of Medicine
- Developer GlaxoSmithKline; GSK
- Class Antineoplastics; Cytokines
- Mechanism of Action Interleukin 18 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Ovarian cancer
- Discontinued Cancer; Malignant melanoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy) in USA (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy) in USA (IV, Infusion)
- 30 Jun 2008 Phase-I clinical trials in Ovarian cancer in USA (IV)